- |||||||||| ADP-A2M4N7X19 - Adaptimmune, Noile / Immune Biotech, afamitresgene autoleucel (ADP-A2M4) / Adaptimmune
IL-7 and CCL19 Expression in Specific Peptide Enhanced Affinity Receptor T-cells Targeting MAGE-A4 Display Improved Survival and Ability to Induce Migration of Immune Cells (Poster Board Number: M-266; Hall D) - Apr 20, 2022 - Abstract #ASGCT2022ASGCT_794;
Here we describe a next-generation SPEAR T-cell therapy (ADP-A2M4N7X19), targeting the MAGE-A4 tumor antigen peptide presented on HLA-A*02:01, that utilizes PRIME technology to secrete IL-7 and CCL19.3 These modifications are hypothesized to enhance proliferative and survival capabilities, as well as infiltration of other immune cells into MAGE-A4-positive tumors...SPEARHEAD-1: A Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma...Nat Biotechnol. 2018;36:346.
|
